Mesirow Financial Investment Management Inc. Buys 10,994 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mesirow Financial Investment Management Inc. lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 129.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 19,494 shares of the biopharmaceutical company's stock after acquiring an additional 10,994 shares during the period. Mesirow Financial Investment Management Inc.'s holdings in Halozyme Therapeutics were worth $932,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the 4th quarter worth $29,000. Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 197 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter valued at about $69,000. Parkside Financial Bank & Trust increased its stake in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 322 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in Halozyme Therapeutics by 173.6% in the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 1,028 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Remove Ads

Halozyme Therapeutics Stock Down 0.9 %

Shares of Halozyme Therapeutics stock traded down $0.56 during trading on Wednesday, hitting $60.89. The company's stock had a trading volume of 1,525,343 shares, compared to its average volume of 1,313,101. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $65.53. The company has a market capitalization of $7.50 billion, a PE ratio of 17.75, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a fifty day simple moving average of $56.24 and a two-hundred day simple moving average of $54.67. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on HALO shares. Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Benchmark restated a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $62.78.

Insider Activity

In other news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock worth $1,754,451 over the last three months. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.